Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Published in: Neurotherapeutics 4/2017

01-10-2017 | Review

Ethical Considerations of Patient-Funded Research for Multiple Sclerosis Therapeutics

Authors: Lilyana Amezcua, Flavia Nelson

Published in: Neurotherapeutics | Issue 4/2017

Login to get access

Abstract

Patient-funded research has started to emerge in multiple sclerosis studies, such as low-dose naltrexone and stem-cell therapy. While these represent greater opportunities for the physician, scientist, and patient, ethical concerns concerning protocol review, conflict of interests, and protection of subjects are reviewed.
Appendix
Available only for authorised users
Literature
1.
Hartung DM, Bourdette DN, Ahmed SM, Whitham RH. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail? Neurology 2015;84:2185-2192.CrossRefPubMedPubMedCentral
2.
Vayena E, Brownsword R, Edwards SJ, et al. Research led by participants: a new social contract for a new kind of research. J Med Ethics 2016;42:216-219.CrossRefPubMed
3.
Vayena E, Tasioulas J. The ethics of participant-led biomedical research. Nat Biotechnol 2013;31:786-787.CrossRefPubMed
4.
Giannuzzi V, Devlieger H, Margari L, et al. The ethical framework for performing research with rare inherited neurometabolic disease patients. Eur J Pediatr 2017;176:395-405.CrossRefPubMedPubMedCentral
5.
6.
Wenner DM, Kimmelman J, London AJ. Patient-funded trials: Opportunity or liability? Cell Stem Cell 2015;17:135-137.CrossRefPubMed
7.
8.
Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol 2010;68:145-150.PubMed
9.
Perry JE, Cox D, Cox AD. Trust and transparency: patient perceptions of physicians' financial relationships with pharmaceutical companies. J Law Med Ethics 2014;42:475-491.CrossRefPubMed
10.
11.
12.
Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012;11:150-156.CrossRefPubMedPubMedCentral
13.
Mancardi GL, Sormani MP, Gualandi F, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology 2015;84:981-988.CrossRefPubMed
14.
Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol 2015;72:159-169.CrossRefPubMedPubMedCentral
15.
Harris VK, Vyshkina T, Sadiq SA. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis. Cytotherapy 2016;18:1476-1482.CrossRefPubMed
16.
Douvaras P, Wang J, Zimmer M, et al. Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis patients by induced pluripotent stem cells. Stem Cell Rep 2014;3:250-259.CrossRef
17.
Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009;8:244-253.CrossRefPubMed
18.
Freedman MS, Cohen JA. Meta-analysis of bone marrow transplantation treatment studies: mixing 'apples and oranges'. Mult Scler 2011;17:131-132.CrossRefPubMed
19.
Simonson OE, Domogatskaya A, Volchkov P, Rodin S. The safety of human pluripotent stem cells in clinical treatment. Ann Med 2015;47:370-380.CrossRefPubMed
20.
Weinfurt KP, Friedman JY, Allsbrook JS, Dinan MA, Hall MA, Sugarman J. Views of potential research participants on financial conflicts of interest: barriers and opportunities for effective disclosure. J Gen Intern Med 2006;21:901-906.CrossRefPubMedPubMedCentral
21.
Harris VK, Yan QJ, Vyshkina T, Sahabi S, Liu X, Sadiq SA. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis. J Neurol Sci 2012;313:167-177.CrossRefPubMed
22.
23.
24.
Klein E, Solomon AJ, Corboy J, Bernat J. Physician compensation for industry-sponsored clinical trials in multiple sclerosis influences patient trust. Mult Scler Relat Disord 2016;8:4-8.CrossRefPubMed
25.
Pham-Kanter G, Mello MM, Lehmann LS, Campbell EG, Carpenter D. Public awareness of and contact with physicians who receive industry payments: a national survey. J Gen Intern Med 2017;32:767-774.CrossRefPubMed
26.
27.
Spelsberg A, Martiny A, Schoenhoefer PS. Is disclosure of potential conflicts of interest in medicine and public health sufficient to increase transparency and decrease corruption? J Epidemiol Commun Health 2009;63:603-605.CrossRef
28.
Kastner B, Behre S, Lutz N, et al. Clinical research in vulnerable populations: variability and focus of institutional review boards' responses. PLOS ONE 2015;10:e0135997.CrossRefPubMedPubMedCentral
29.
Gehring K, Sitskoorn MM, Aaronson NK, Taphoorn MJ. Interventions for cognitive deficits in adults with brain tumours. Lancet Neurol 2008;7:548-560.CrossRefPubMed
30.
28. Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology 2004;62(5 Suppl. 2):S24-S29.
31.
Schwenzer KJ. Protecting vulnerable subjects in clinical research: children, pregnant women, prisoners, and employees. Respir Care 2008;53:1342-1349.PubMed
32.
33.
Khan O, Williams MJ, Amezcua L, Javed A, Larsen KE, Smrtka JM. Multiple sclerosis in US minority populations: clinical practice insights. Neurol Clin Pract 2015;5:132-142.CrossRefPubMedPubMedCentral
34.
Shabas D, Heffner M. Multiple sclerosis management for low-income minorities. Mult Scler 2005;11:635-640.CrossRefPubMed
35.
36.
Morgan-Followell BN, Nicholas JA, Weisleder P. Reproductive issues in women with multiple sclerosis: ethical considerations. Continuum (Minneap Minn) 2014;20:177-180.
Metadata
Title
Ethical Considerations of Patient-Funded Research for Multiple Sclerosis Therapeutics
Authors
Lilyana Amezcua
Flavia Nelson
Publication date
01-10-2017
Publisher
Springer US
Published in
Neurotherapeutics / Issue 4/2017
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-017-0560-9

Other articles of this Issue 4/2017

Neurotherapeutics 4/2017 Go to the issue

Erratum

Erratum to: Chronic Paroxetine Treatment Prevents the Emergence of Abnormal Electroencephalogram Oscillations in Huntington’s Disease Mice

Review

Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA

Review

Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis

Review

Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials

Original Article

Effectiveness of Daily Prednisolone to Slow Progression of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Multicenter Retrospective Cohort Study

Review

Pregnancy: Effect on Multiple Sclerosis, Treatment Considerations, and Breastfeeding